BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Patients With Mantle Cell Lymphoma; Treatment Reduced Risk Of Progression Or Death By 43%

뉴스 본문을 불러오고 있어요.

BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Patients With Mantle Cell Lymphoma; Treatment Reduced Risk Of Progression Or Death By 43% | 웨이프 WAPE

BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Patients With Mantle Cell Lymphoma; Treatment Reduced Risk Of Progression Or Death By 43%

기사 요약

관련 종목

댓글 —